Improving Outcomes in R/R AML: Can Unique Combinations of Novel Agents Impact Prognosis? Early Trial Results of Venetoclax + Idasanutlin and Azacitidine + Nivolumab, Azacitidine + Ipilimumab with Naval Daver, MD

767. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (ida) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

906. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

Maximizing Efficacy Across the Spectrum of AML: Early Clinical Trial Results of the FLT3 Inhibitor Quizartinib in Newly Diagnosed and Relapsed/Refractory AML with Mark J. Levis, MD, PhD

563. Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

564. Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
The Clinical Challenge of Older AML Patients Ineligible for Intensive Chemotherapy: Clinical Trial Results of Venetoclax in Combination with Cytarabine and HMAs
with Daniel A. Pollyea, MD

285. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

284. Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

The Emerging Role of Bispecific Antibodies in AML: Promising Early Trial Results
with Farhad Ravandi, MD

25. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

763. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
Ivosidenib and Enasidenib: Do These IDH Inhibitors Impact Survival in Newly Diagnosed AML Patients? with Eytan M. Stein, MD

560. Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

561. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Newer Generation Antibody-Drug Conjugates: Is There a Future For Monotherapy and/or Combination Strategies with Oral Agents in AML? with Eunice S. Wang, MD

26. Maturing Clinical Profile of IMGN779. A Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

2647. Synergistic Anti-Leukemic Activity of PARP Inhibition Combine with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models